NASDAQ · Biotechnology · USD
Acurx Pharmaceuticals, Inc. (ACXP) Stock Analysis
Acurx Pharmaceuticals, Inc. (ACXP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ACXP Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.18
- Previous Close
- $1.14
- Day's Range
- 1.14–1.18
- 52-Week Range
- 1.07–7.54
- Volume
- 20.96K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −2.05
Valuation
- Market Cap
- $6.39M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.67
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$7.97M
- Shares Outstanding
- 5.56M
- 1-Year Return
- −83.59%
Dividend and dates
- Earnings Date
- November 11, 2026estimated
- Avg Volume
- 123.19K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ACXP closed at $1.15, −83.59% over 1 year.
Acurx Pharmaceuticals, Inc. (ACXP) has a market capitalization of $6.39M.
In fiscal 2025, ACXP reported revenue of $0.00.
ACXP Stock Return by Calendar Year
Acurx Pharmaceuticals, Inc. (ACXP) return since Jun 2021: what $10,000 became
- 1 year
- $10,000 $1,641
- −83.59%
- 5 years
- $10,000 $115
- −98.85%
- Since Jun 2021
- $10,000 $73
- −99.27%
If you had invested $10,000 in Acurx Pharmaceuticals, Inc. (ACXP) at the close on June 25, 2021, the earliest close on record here, it would have been worth $73 at the close on October 21, 2026: −99.27% in total, −60.33% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −53.82% |
| 2025 | −84.71% |
| 2024 | −78.75% |
| 2023 | −3.77% |
| 2022 | −7.89% |
| 2021 (partial year) | −45.23% |
As of October 21, 2026.
ACXP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$7.97M | — |
| 2024 | $0.00 | −$14.10M | — |
| 2023 | $0.00 | −$14.58M | — |
| 2022 | $0.00 | −$12.09M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$8.09M | −$7.97M | — |
| 2024 | $0.00 | — | −$14.12M | −$14.10M | — |
| 2023 | $0.00 | — | −$14.58M | −$14.58M | — |
| 2022 | $0.00 | — | −$12.09M | −$12.09M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
YahooAcurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
YahooHC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target
BenzingaAcurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection
BenzingaNew to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
YahooTranscript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Benzinga
All 12 articles ↓Show fewer ↑
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
YahooAcurx Pharmaceuticals Files Prospectus For 1.5M Offering
BenzingaFDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat
BenzingaAcurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
SeekingAlphaAcurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
BenzingaAcurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B